PER 1.23% 8.0¢ percheron therapeutics limited

next ann:initiation of phase iia trial atl1103, page-9

  1. 2,315 Posts.
    lightbulb Created with Sketch. 11
    A great announcement…

    “Afandin has advised ANP that it has made significant progress in attracting interest in the further development of ATL1101 and is currently in discussions with a number of corporate and investor groups, some of which are currently undertaking due diligence on ATL1101.”

    Certainly is a positive out looking statement. This will be worth tens of millions to ANP sometime over the next 6 months - conclusion should be made and announced well before the 6 month deadline imo

    Also is more firepower for the share price in the not too distant future…. there really is a cocktail of re-rating news surrounding ANP now.

    I wonder how negotiations for tie-in are coming along...


    Good Luck All!
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.